Fintel reports that on November 4, 2025, D. Boral Capital maintained coverage of MediciNova (NasdaqGM:MNOV) with a Buy recommendation.
Analyst Price Forecast Suggests 395.83% Upside
As of October 30, 2025, the average one-year price target for MediciNova is $7.14/share. The forecasts range from a low of $5.05 to a high of $9.45. The average price target represents an increase of 395.83% from its latest reported closing price of $1.44 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for MediciNova is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -0.35.
What is the Fund Sentiment?
There are 37 funds or institutions reporting positions in MediciNova. This is an decrease of 7 owner(s) or 15.91% in the last quarter. Average portfolio weight of all funds dedicated to MNOV is 0.02%, an increase of 15.87%. Total shares owned by institutions decreased in the last three months by 1.03% to 5,848K shares. 
The put/call ratio of MNOV is 0.02, indicating a bullish outlook.
What are Other Shareholders Doing?
Essex Woodlands Management holds 1,106K shares representing 2.25% ownership of the company. No change in the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 671K shares representing 1.37% ownership of the company. In its prior filing, the firm reported owning 608K shares , representing an increase of 9.39%. The firm decreased its portfolio allocation in MNOV by 10.99% over the last quarter.
Citigroup holds 592K shares representing 1.21% ownership of the company. No change in the last quarter.
Geode Capital Management holds 526K shares representing 1.07% ownership of the company. In its prior filing, the firm reported owning 527K shares , representing a decrease of 0.21%. The firm decreased its portfolio allocation in MNOV by 57.65% over the last quarter.
FSMAX - Fidelity Extended Market Index Fund holds 269K shares representing 0.55% ownership of the company. In its prior filing, the firm reported owning 265K shares , representing an increase of 1.56%. The firm decreased its portfolio allocation in MNOV by 9.74% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
